EventHealthSeptember 23, 2026

Enveda raises $311M to advance AI-discovered natural drugs

Read original source →techcrunch.com

The Series E, led by Catalio Capital Management with Iconiq participating, values the AI biotech at $2 billion — double its valuation 12 months ago. Enveda is testing candidates for severe skin conditions and for maintaining weight loss after stopping GLP-1s.

1 source

More stories today

Open the live feed